SkyCell Revolutionizes Pharmaceutical Supply Chain Management
June 26, 2024, 3:54 am
Location: Switzerland, Zurich
Employees: 51-200
Founded date: 2013
Total raised: $271.67M
SkyCell, a Swiss-based technology company, has secured a staggering $116 million in Series D funding to further expand its global footprint and drive growth in the US and Asia. The company's innovative approach to pharmaceutical supply chain management has garnered significant attention and investment from key players in the industry.
SkyCell's cutting-edge technology combines proprietary software, hardware, and big data analytics to create temperature-controlled door-to-door container solutions that revolutionize the way pharmaceutical companies transport sensitive drugs. By reducing and predicting risks associated with air transportation, SkyCell ensures that healthcare systems are protected and that medications reach consumers safely and efficiently.
With a focus on sustainability, SkyCell has committed to reducing CO2 emissions and has already achieved a market-leading low in-transit failure rate of less than 0.05% temperature excursions. The company's climate-neutral approach and goal of achieving end-to-end net-zero by 2040 demonstrate its dedication to creating a more sustainable future for the pharmaceutical industry.
SkyCell's success is built on its proprietary cold chain technology and software platform, SkyMind, which streamlines shipment and asset management through automation and real-time visibility. The company's containers protect over $2.5 billion worth of pharmaceutical goods each month, including vaccines, cancer treatments, and diagnostic solutions for patients worldwide.
The recent Series D funding round, which closed at $116 million, saw the addition of two new investors, Tybourne Capital Management and CCI, who recognize the importance of decarbonizing the pharmaceutical supply chain. SkyCell's commitment to reducing CO2 emissions and supporting pharma customers in their decarbonization journey has positioned the company as a leader in cold-chain logistics and technology solutions.
Richard Ettl, CEO of SkyCell, expressed excitement about the company's role in supporting the pharmaceutical industry's growth and decarbonization efforts. With the latest funding infusion, SkyCell aims to optimize supply chains, reduce costs, and create sustainable logistics solutions that benefit both the industry and the environment.
In a rapidly evolving pharmaceutical landscape, SkyCell's innovative approach to supply chain management is transforming the industry and setting new standards for efficiency, sustainability, and excellence. As global supply chains become increasingly complex, SkyCell's comprehensive system of hardware, software, and analytics is revolutionizing pharmaceutical logistics and ensuring that life-saving medications reach patients in need.
SkyCell's cutting-edge technology combines proprietary software, hardware, and big data analytics to create temperature-controlled door-to-door container solutions that revolutionize the way pharmaceutical companies transport sensitive drugs. By reducing and predicting risks associated with air transportation, SkyCell ensures that healthcare systems are protected and that medications reach consumers safely and efficiently.
With a focus on sustainability, SkyCell has committed to reducing CO2 emissions and has already achieved a market-leading low in-transit failure rate of less than 0.05% temperature excursions. The company's climate-neutral approach and goal of achieving end-to-end net-zero by 2040 demonstrate its dedication to creating a more sustainable future for the pharmaceutical industry.
SkyCell's success is built on its proprietary cold chain technology and software platform, SkyMind, which streamlines shipment and asset management through automation and real-time visibility. The company's containers protect over $2.5 billion worth of pharmaceutical goods each month, including vaccines, cancer treatments, and diagnostic solutions for patients worldwide.
The recent Series D funding round, which closed at $116 million, saw the addition of two new investors, Tybourne Capital Management and CCI, who recognize the importance of decarbonizing the pharmaceutical supply chain. SkyCell's commitment to reducing CO2 emissions and supporting pharma customers in their decarbonization journey has positioned the company as a leader in cold-chain logistics and technology solutions.
Richard Ettl, CEO of SkyCell, expressed excitement about the company's role in supporting the pharmaceutical industry's growth and decarbonization efforts. With the latest funding infusion, SkyCell aims to optimize supply chains, reduce costs, and create sustainable logistics solutions that benefit both the industry and the environment.
In a rapidly evolving pharmaceutical landscape, SkyCell's innovative approach to supply chain management is transforming the industry and setting new standards for efficiency, sustainability, and excellence. As global supply chains become increasingly complex, SkyCell's comprehensive system of hardware, software, and analytics is revolutionizing pharmaceutical logistics and ensuring that life-saving medications reach patients in need.